RLD2101

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

GastritisHealthy Adult Volunteer

Phase 1

Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers

CompletedNCT04967014

Hanmi Pharmaceutical Company LimitedHealthy Adult Volunteer

Start: 2021-05-06End: 2021-06-18Updated: 2021-07-19

Phase 3

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

CompletedNCT05024721

Hanmi Pharmaceutical Company LimitedGastritis

Start: 2021-08-09End: 2022-03-07Updated: 2022-07-14

Related Papers

Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study

Gut and Liver2025-02-141 citations

Pharmacodynamics Between a Dual Delayed-Release Formulation of Low-Dose Esomeprazole and Famotidine in Healthy Korean Subjects.

2024-07-20